%0 Journal Article
%T Actual Data on the Efficacy and Safety of Gemcitabine-Docetaxel as Second-Line and Beyond Treatment in Adult Patients with Metastatic Bone Sarcomas: Experience from a Single Institution
%A Medyouni Hajar
%A Chouef Jihane
%A Siyouri Oumaima
%A Chbihi Chaymae
%A Mhirech Samia
%A Amaadour Lamiae
%A Oualla Karima
%A Benbrahim Zineb
%A Arifi Samia
%A Mellas Nawfel
%J Open Access Library Journal
%V 11
%N 4
%P 1-6
%@ 2333-9721
%D 2024
%I Open Access Library
%R 10.4236/oalib.1111414
%X Osteosarcoma, the most prevalent primary malignant bone tumor in children, presents significant challenges in treatment, particularly in cases of recurrence or refractory disease. This retrospective study explores the efficacy and safety of gemcitabine-docetaxel (GD) combination therapy as second-line or later treatment in adult patients with advanced bone sarcomas. Twenty-two patients received GD, with 64% showing overall disease control. Median progression-free survival (PFS) was 5 months, and median overall survival (OS) was 8.5 months. Adverse events were manageable, with mainly myelosuppression observed, principally neutropenia followed by anemia and thrombocytopenia, (grade 1 - 2). Despite limitations such as retrospective design and small sample size, GD demonstrated tolerability and modest efficacy, offering a potential treatment option for refractory or recurrent high-grade osteosarcoma where limited alternatives exist.
%K Bone sarcomas
%K Metastatic
%K Recurrent
%K Gemcitabine
%K Docetaxel
%U http://www.oalib.com/paper/6820222